Contreras Loreto, Mercado Loreto, Delgado Carolina, Cabezas Claudia, Starke Laksmi, Romero Mónica, Ibieta Fernando, Henríquez Mauricio, Chandia Mauricio
Unidad de Anatomía Patológica, Hospital Dr. Guillermo Grant Benavente, Concepción, Chile.
Unidad de Hematología, Hospital Dr. Guillermo Grant Benavente, Concepción, Chile.
Rev Med Chil. 2017 Jan;145(1):115-120. doi: 10.4067/S0034-98872017000100015.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that most commonly manifests as cutaneous lesions with or without bone marrow involvement and leukemic dissemination. The demonstration of tumor cells with the characteristic immunophenotype with expression of CD56, generally CD4 and dendritic cell antigens (CD123, cyTCL-1, HLA-DR), in the absence of myeloid or lymphoid lineage markers is required for the diagnosis. Responses to chemotherapy are initially satisfactory, with frequent systemic and central nervous system relapses. We report a 24 year-old male with BPDCN, initially diagnosed and treated as non-Hodgkin CD4+ T-cell lymphoma, with initial complete remission who evolved with early central nervous system relapse. A second attempt of chemotherapy failed and the patient died two months later.
母细胞性浆细胞样树突状细胞肿瘤(BPDCN)是一种罕见的、临床侵袭性血液系统恶性肿瘤,最常见的表现是伴有或不伴有骨髓受累及白血病播散的皮肤损害。诊断需要证实肿瘤细胞具有特征性免疫表型,表达CD56,通常还有CD4和树突状细胞抗原(CD123、cyTCL-1、HLA-DR),且不存在髓系或淋巴系谱系标志物。化疗初期反应良好,但常出现全身和中枢神经系统复发。我们报告一名24岁男性患有BPDCN,最初被诊断并当作非霍奇金CD4 + T细胞淋巴瘤进行治疗,初始完全缓解,但随后出现早期中枢神经系统复发。第二次化疗尝试失败,患者两个月后死亡。